- Ziopharm Oncology (NASDAQ:ZIOP) updates investors on key pipeline programs ahead of its JPM18 presentation Thursday morning, January 11.
- Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma: a Phase 1 study demonstrated the safety of controlled expression of interleukin-12 (IL-12) which can turn cold tumors hot making potentially making the tumor cells more receptive to immunotherapies.
- Phase 1 study initiated assessing the combo with Bristol-Myers Squibb's Opdivo (nivolumab) in adult patients with recurrent glioblastoma. Pivotal study will be launched in H2. Partnership discussions ongoing for the indication.
- CAR T therapies being advanced, in collaboration with Intrexon (NYSE:XON). First point-of-care clinical trial evaluating the non-viral Sleeping Beauty platform will be initiated this year.
- Phase 1 study of CD33-specific CAR+T therapy in acute myeloid leukemia underway at MD Anderson in Houston.
- Shares are off 1% premarket on light volume.
- #JPM18
- Now read: ZIOPHARM Oncology (ZIOP) Reports Positive Upadte Results of Ad-RTS-hIL-12 Study in Brain Cancer - Slideshow
Original article